期刊文献+

rhIL-11对急性非淋巴细胞白血病儿童强烈化疗后血小板减少的防治作用

下载PDF
导出
摘要 目的:研究重组人白细胞介素-11(rhIL-11)对急性非淋巴细胞白血病(急非淋)强烈化疗后血小板减少的防治作用。方法:rhIL-11组于化疗结束后24h皮下注射rhIL-1150μg·kg-1·d-1,连用10~14d;对照组不用rhIL-11,观察两组血小板减低持续时间、血小板输注量及血小板计数变化情况及不良反应的发生情况。结果:与对照组比,rhIL-11组患者血小板数量明显增加、血小板减低持续时间缩短,血小板输注量减少。不良反应以乏力、水肿和注射部位疼痛为主。结论:hIL-11对急非淋强烈化疗后血小板减少有明显的预防和治疗作用,不良反应轻微,与化疗联用可减少出血并发症,使化疗顺利进行。
出处 《温州医学院学报》 CAS 2007年第4期384-385,共2页 Journal of Wenzhou Medical College
  • 相关文献

参考文献8

  • 1Tepler I,Elias L,Smith JW 2nd,et al.A randomized placebocontrolled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy[J].Blood,1996,87(9):3607-3614.
  • 2Isaacs C,Robert NJ.Bailey FA,et al.Randomized placebocontrolled study of recombinant human interleukin-11 to prevent.chemotherapy-induced thrombocytopenia in patients with breast.cancer receiving dose-intensive cyclophosphamide and doxorubicin[J].J Clin Oncol,1997,15(11):3368-3377.
  • 3Schwertschlag US,Trepicchio WL,Dykstra KH,et al.Hematopoietic,immunomodulatory and epithelial effects of interleukin-11[J].Leukemia,1999,13(9):1307-1315.
  • 4Turner KJ,Goldman SJ,Kaye IA,et al.Thrombopoiesis and thrombopoietin:the significance of "non-TPO" cytokines[J].Blood,1996,87(7):3065-3067.
  • 5Weich NS,Warg A,Fitgerald M,et al.Recombinant human interleukin-11 directly promotes megakaryocytopoiesis[J].Blood,1997,90(10):3893-3902.
  • 6孙晓非,管忠震,黄河,周清华,易成,张力健,朱军,李蓉,周娟,张梅,郭颖.重组人白细胞介素11预防和治疗血小板降低的临床研究报告[J].癌症,2002,21(8):892-895. 被引量:41
  • 7唐锁勤,杨光,王建文,黄东生,于芳,刘英.重组人白细胞介素-11防治神经母细胞瘤患儿强烈化疗后血小板减少的自身对照研究[J].实用儿科临床杂志,2005,20(7):657-659. 被引量:3
  • 8Reynolds,CH.Clinical efficacy of rhIL-11[J].Oncolongy (Williston Park),2000,14(9 Suppl 8):32-40.

二级参考文献10

  • 1苗战会,路平.拓扑替康联合治疗复发和难治性神经母细胞瘤[J].实用儿科临床杂志,2004,19(7):584-585. 被引量:3
  • 2[1]Isaacs C,Robert NJ,Bailey FA,et al. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin [J]. J Clin Oncol, 1997, 15:3368- 3377.
  • 3[2]John W, Smith H. Tolerability and side-effect profile of rhIL-11 [J]. Oncology,2000,14(9):41- 47.
  • 4Opal SM, Depalo VA. Anti-inflammatory cytokines[J].Chest,2000,117:1162.
  • 5Schwertschlag US, Trepicchio WL, Dykstra KH,et al.Hematopoietic, immunomodulatory and epithelial effects of interleukin-11[J].Leukemia,1999,13:1307.
  • 6Isaacs C, Robert NJ, Bailey FA,et al.Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin[J].J Clin Oncol,1997,15:3368.
  • 7Goldman SC, Bracho F, Davenport V,et al. Feasibility study of IL-11 and granulocyte colony-stimulating factor after myelosuppressive chemotherapy to mobilize peripheral blood stem cells from heavily pretreated patients[J].J Pediatr Hematol Oncol,2001,23:300.
  • 8Grosfeld JL, Du X,Williams DA. Interleukin-11:its biology and prospects for clinical use[J].J Parenteral Enteral Nutrition,1999,23(suppl):S67.
  • 9高晓宁,唐锁勤,张晓飞,杨光,刘英,于芳.S100A4反义核酸抑制神经母细胞瘤细胞侵袭的作用[J].实用儿科临床杂志,2004,19(3):204-206. 被引量:4
  • 10余永国,高清平.白细胞介素-11对急性淋巴细胞白血病幼龄小鼠骨髓移植后的影响[J].实用儿科临床杂志,2004,19(6):480-483. 被引量:2

共引文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部